Literature DB >> 9228358

Short-term incarceration for the management of noncompliance with tuberculosis treatment.

W J Burman1, D L Cohn, C A Rietmeijer, F N Judson, J A Sbarbaro, R R Reves.   

Abstract

STUDY
OBJECTIVES: To review the use of incarceration for noncompliance with tuberculosis treatment.
DESIGN: Retrospective review.
SETTING: An urban tuberculosis control program. PATIENTS: Patients treated for active tuberculosis. MEASUREMENTS AND
RESULTS: We reviewed the legal basis and practical application of quarantine for active tuberculosis, including the use of incarceration for noncompliance. The records of patients treated at the Denver Metro Tuberculosis Clinic during 1984 to 1994 were reviewed to identify patients who were incarcerated and to evaluate the effectiveness of this intervention. Of 424 cases of tuberculosis, 20 patients (4.7%) were incarcerated for noncompliance; an additional 21 patients (5.0%) were lost to follow-up prior to completing therapy. Incarcerated patients were predominantly men who were born in the United States and had a history of homelessness and alcohol abuse. The median duration of the initial incarceration was 20 days (range, 7 to 51 days). Of the 17 patients released prior to completing therapy, 13 (76%) were compliant with outpatient, directly observed therapy after one or two short-term incarcerations (<60 days); only three patients were incarcerated for the duration of treatment. Overall, 18 of 20 incarcerated patients (90%) were successfully treated.
CONCLUSIONS: Approximately 5% of the patients treated through our program were incarcerated for noncompliance; an additional 5% were unavailable for follow-up and would have been candidates for incarceration if found. Homelessness and alcoholism were closely associated with the use of incarceration. Short-term incarceration followed by outpatient, directly observed therapy was relatively successful in the management of this difficult patient population.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9228358     DOI: 10.1378/chest.112.1.57

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  9 in total

1.  Tuberculosis in Seattle, 1949-1973: balancing public health and civil liberties.

Authors:  B H Lerner
Journal:  West J Med       Date:  1999-07

Review 2.  Current medical treatment for tuberculosis.

Authors:  Edward D Chan; Michael D Iseman
Journal:  BMJ       Date:  2002-11-30

3.  Implementing tuberculosis control in Papua New Guinea: a clash of culture and science?

Authors:  Kindin Ongugo; John Hall; John Attia
Journal:  J Community Health       Date:  2011-06

4.  Skin-test screening and tuberculosis transmission among the homeless.

Authors:  Po-Marn Kong; Jan Tapy; Patricia Calixto; William J Burman; Randall R Reves; Zhenhua Yang; M Donald Cave
Journal:  Emerg Infect Dis       Date:  2002-11       Impact factor: 6.883

5.  Alcohol use and clinical manifestations of tuberculosis.

Authors:  Christina T Fiske; Carol D Hamilton; Jason E Stout
Journal:  J Infect       Date:  2008-10-09       Impact factor: 6.072

6.  Alcohol use and clinical manifestations of tuberculosis.

Authors:  Christina T Fiske; Carol D Hamilton; Jason E Stout
Journal:  J Infect       Date:  2009-05       Impact factor: 6.072

7.  Does directly observed therapy (DOT) reduce drug resistant tuberculosis?

Authors:  Patrick K Moonan; Teresa N Quitugua; Janice M Pogoda; Gary Woo; Gerry Drewyer; Behzad Sahbazian; Denise Dunbar; Kenneth C Jost; Charles Wallace; Stephen E Weis
Journal:  BMC Public Health       Date:  2011-01-07       Impact factor: 3.295

8.  XDR-TB in South Africa: no time for denial or complacency.

Authors:  Jerome Amir Singh; Ross Upshur; Nesri Padayatchi
Journal:  PLoS Med       Date:  2007-01       Impact factor: 11.069

9.  The power of detention in the management of non-compliance with tuberculosis treatment: a survey of Irish practitioners and analysis of potential legal liability.

Authors:  S T Duffy
Journal:  Public Health       Date:  2008-12-16       Impact factor: 2.427

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.